Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Deals·Zenflow

Cook Medical leads Zenflow's $52M round and takes over U.S. sales of its prostate implant

Cook Medical led Zenflow's oversubscribed $52 million Series D and will be the exclusive U.S. distributor of the Zenflow Spring, an in-office implant for enlarged prostate that the FDA approved in December 2025.

Charted Staff2 min read
From Zenflow and Cook Medical announcements published Oct. 5, 2026, and earlier Zenflow and Cook Medical announcements from November 2024
An illustration of the prostate before and after placement of the Zenflow Spring implant.
An illustration of the prostate before and after placement of the Zenflow Spring implant.Courtesy of Cook Medical
Amount
$52M
Type
Series D
Company
Zenflow
Lead investor
Cook Medical
Sector
Medtech
Announced
Oct. 5, 2026

Cook Medical invested in Zenflow before its prostate implant had Food and Drug Administration approval. Now that the device is approved, Cook is putting in more money and taking over the selling.

Zenflow Inc. said Oct. 5 that Cook led its oversubscribed $52 million Series D round and signed on as the exclusive U.S. distributor of the Zenflow Spring System, an implant the South San Francisco, Calif., company says treats benign prostatic hyperplasia (BPH), or enlarged prostate, in a doctor's office.

Why it matters: The agreement turns Zenflow's lead strategic investor into its route to market. Zenflow will reach U.S. urologists through Cook, which pointed in its own announcement to its commercial infrastructure and its relationships with those physicians.

ClavystBio joined the round as a new investor, alongside existing backers Invus Opportunities, F-Prime and Medtech Venture Partners, among others. HSBC Bank USA and Trinity Capital added venture debt, Zenflow said. Neither company disclosed the size of the debt facility, a valuation or the financial terms of the distribution deal.

From backer to distributor

Cook's first check came in November 2024, when it led a $24 million Series C. Zenflow said then that the money would pay for its premarket approval application to the FDA and preparation for a commercial launch.

The FDA approved the Spring System in December 2025 through the premarket approval pathway, the agency's route for the highest-risk devices, Zenflow said. In September 2026, the company announced that four U.S. centers had completed procedures with the implant. Proceeds from the Series D will go toward speeding up the commercial launch, Zenflow said.

"Our initial investment in Zenflow reflected our confidence in both the technology and the team," DJ Sirota, senior vice president of Cook Medical's MedSurg division, said in Cook's announcement. Cook, based in Bloomington, Ind., said the implant joins its line of prostate health products.

Andrew Cleeland, Zenflow's board chairman, said in Zenflow's release that joining Zenflow's operations to Cook's sales know-how would speed up the launch.

The device and the market

Zenflow describes the Spring System as a minimally invasive, in-office BPH treatment that comes in multiple sizes and can be fully reversed. Cook describes it as a nitinol implant placed in the urethra during an office procedure that, according to Cook, involves no incisions, no general anesthesia and no tissue removal. When it announced its 2024 investment, Cook described the device as a small spring-like coil that props the urethra open.

The companies are positioning the implant as what they call first-line interventional therapy: a device-based alternative to medication. Zenflow cited published estimates that BPH affects 32 million U.S. men over 60 and 79 million men globally.

"Cook Medical's deep relationships within urology and proven commercialization capabilities make them the ideal partner," Shreya Mehta, Zenflow's chief executive, said.

What to watch

The open question is timing. Cook said details on commercial availability through its network and on rollout timelines would come later. The companies have not said how many centers are now offering the procedure beyond the four Zenflow announced in September, or how the device will be priced.

Stories bylined Charted Staff are produced by the Charted newsroom from public documents: company announcements, SEC filings, FDA databases and federal rules. Each one lists the documents it was drawn from. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Deals

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.